The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Kiselev A.V.

N.N. Semenov Institute of Chemical Physics, Russian Academy of Sciences, Moscow, Russia

Vostrikova E.V.

Kafedra klinicheskoĭ nevrologii i algologii GBOU VPO "Novosibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet" Minzdrava Rossii, Novosibirsk

Kalinina T.S.

Zakusov Institute of Pharmacology, Moscow, Russia

Stovbun S.V.

Institut khimicheskoĭ fiziki im. N.N. Semenova RAN, Moskva

A randomized, double-blind, placebo-controlled study of the efficacy and safety of ampasse in the treatment of chronic cerebral ischemia

Authors:

Kiselev A.V., Vostrikova E.V., Kalinina T.S., Stovbun S.V.

More about the authors

Views: 3806

Downloaded: 112


To cite this article:

Kiselev AV, Vostrikova EV, Kalinina TS, Stovbun SV. A randomized, double-blind, placebo-controlled study of the efficacy and safety of ampasse in the treatment of chronic cerebral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(4):21‑25. (In Russ.)
https://doi.org/10.17116/jnevro201911904121

Recommended articles:
Neurometabolic therapy of mild cognitive impairment in patients with chro­nic cere­bral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):42-51
A clinical case of the new-onset bipo­lar affe­ctive diso­rder in the postcovid period. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):125-129
Targeting NMDAR/AMPAR: a promising pharmacotherapeutic approach for depressive diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):22-30

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.